257 related articles for article (PubMed ID: 30762246)
41. Intermediate doses of rituximab used as adjuvant therapy in refractory pemphigus.
Londhe PJ; Kalyanpad Y; Khopkar US
Indian J Dermatol Venereol Leprol; 2014; 80(4):300-5. PubMed ID: 25035353
[TBL] [Abstract][Full Text] [Related]
42. Comparing early and late treatments with rituximab in pemphigus vulgaris: which one is better?
Balighi K; Daneshpazhooh M; Mahmoudi H; Badakhsh M; Teimourpour A; Ehsani AH; Azizpour A; Akbari Z; Mahdavinia M; Ghasemiadl M; Tavakolpour S
Arch Dermatol Res; 2019 Jan; 311(1):63-69. PubMed ID: 30506422
[TBL] [Abstract][Full Text] [Related]
43.
Ferranti M; Tadiotto Cicogna G; Sattin A; Alaibac M
BMJ Case Rep; 2018 Dec; 11(1):. PubMed ID: 30567283
[TBL] [Abstract][Full Text] [Related]
44. Nocardiosis in a patient with pemphigus foliaceus treated with rituximab.
Yiğit D; Balta İ; Yiğit H; Ekşioğlu HM
Dermatol Ther; 2021 Jan; 34(1):e14601. PubMed ID: 33247992
[TBL] [Abstract][Full Text] [Related]
45. Rituximab in severe pemphigus.
Schmidt E; Goebeler M; Zillikens D
Ann N Y Acad Sci; 2009 Sep; 1173():683-91. PubMed ID: 19758216
[TBL] [Abstract][Full Text] [Related]
46. Network meta-analysis-based comparison of first-line steroid-sparing adjuvants in the treatment of pemphigus vulgaris and pemphigus foliaceus.
Lee MS; Yeh YC; Tu YK; Chan TC
J Am Acad Dermatol; 2021 Jul; 85(1):176-186. PubMed ID: 32798583
[TBL] [Abstract][Full Text] [Related]
47. Evaluation of cardiac function in patients with pemphigus vulgaris before and after rituximab infusion.
Jafari M; Pighgahi M; Shahidi-Dadras M; Ghalamkarpour F; Tehranchinia Z; Abdollahimajd F; Moravvej H; Robati RM; Mozafari N; Namazi N; Diab R; Razzaghi Z; Toudeshki KK; Dadkhahfar S; Nasiri S
Arch Dermatol Res; 2024 May; 316(5):170. PubMed ID: 38734780
[No Abstract] [Full Text] [Related]
48. Clinical efficacy of rituximab in the treatment of pemphigus: A retrospective study.
Sharma VK; Bhari N; Gupta S; Sahni K; Khanna N; Ramam M; Sethuraman G
Indian J Dermatol Venereol Leprol; 2016; 82(4):389-94. PubMed ID: 27279296
[TBL] [Abstract][Full Text] [Related]
49. Rituximab-induced psoriasis in a patient with pemphigus foliaceous: A case report and literature review.
Charoenpipatsin N; Chularojanamontri L; Rujitharanawong C; Tuchinda P; Kulthanan K
J Dermatol; 2022 Aug; 49(8):e251-e252. PubMed ID: 35384046
[No Abstract] [Full Text] [Related]
50. Paraneoplastic pemphigus associated with fatal bronchiolitis obliterans and intractable mucosal erosions: Treatment with cyclosporin in addition to steroid, rituximab and intravenous immunoglobulin.
Namba C; Tohyama M; Hanakawa Y; Murakami M; Shirakata Y; Matsumoto T; Suemori K; Ishii N; Hashimoto T; Sayama K
J Dermatol; 2016 Apr; 43(4):419-22. PubMed ID: 26506947
[TBL] [Abstract][Full Text] [Related]
51. Rituximab therapy in pemphigus: A long-term follow-up.
Loi C; Magnano M; Ravaioli GM; Sacchelli L; Patrizi A; Bardazzi F
Dermatol Ther; 2019 Jan; 32(1):e12763. PubMed ID: 30288877
[No Abstract] [Full Text] [Related]
52. Treatment of severe pemphigus foliaceus with rituximab.
Fernando SL; O'Connor KS
Med J Aust; 2008 Sep; 189(5):289-90. PubMed ID: 18759729
[No Abstract] [Full Text] [Related]
53. Clinical resolution of pemphigus vulgaris on rituximab.
Cusick E; Silverstein D
Dermatol Online J; 2017 Sep; 23(9):. PubMed ID: 29469734
[TBL] [Abstract][Full Text] [Related]
54. Coexistence case of bullous pemphigoid and pemphigus foliaceus.
Tsujiwaki M; Abe R; Nomura Y; Nishimura M; Hoshina D; Shinkuma S; Natsuga K; Ujiie H; Arita K; Shimizu H
Eur J Dermatol; 2013; 23(4):552-3. PubMed ID: 24001742
[No Abstract] [Full Text] [Related]
55. Rituximab-induced new onset palmo-plantar pustulosis in patients with pemphigus foliaceus: A rare adverse effect.
Neema S; Vendhan S; Vasudevan B; Kashif AW; Thombre R
Dermatol Ther; 2022 Sep; 35(9):e15714. PubMed ID: 35821203
[No Abstract] [Full Text] [Related]
56. Painful ulceration of the vulva.
Gómez Moyano E; Ayala Blanca M; Martínez Pilar L
Am J Obstet Gynecol; 2019 Oct; 221(4):359-360. PubMed ID: 30690013
[No Abstract] [Full Text] [Related]
57. Rituximab treatment of pemphigus in women of childbearing age: experience with two patients.
Lake EP; Huang YH; Aronson IK
J Dermatolog Treat; 2017 Dec; 28(8):751-752. PubMed ID: 27796136
[TBL] [Abstract][Full Text] [Related]
58. Applicability of glucocorticoid toxicity index in pemphigus: Comparison between two groups of rituximab-treated and rituximab-naïve patients.
Mazaherpour E; Kianfar N; Dasdar S; Sedaghat M; Seyrafi H; Balighi K; Saberi F; Nili A; Farimani Z; Azar PM; Mahmoodi H; Murrell DF; Daneshpazhooh M
Dermatol Ther; 2022 Dec; 35(12):e15902. PubMed ID: 36200713
[TBL] [Abstract][Full Text] [Related]
59. Early rituximab treatment is associated with increased and sustained remission in pemphigus patients: A retrospective cohort of 99 patients.
Nosrati A; Mimouni T; Hodak E; Gdalevich M; Oren-Shabtai M; Levi A; Mimouni D; Leshem YA
Dermatol Ther; 2022 May; 35(5):e15397. PubMed ID: 35194896
[TBL] [Abstract][Full Text] [Related]
60. RF-Rituximab: Revolutionizing the Treatment of Pemphigus.
Morgado-Carrasco D; Giavedoni P; Fustà-Novell X; Iranzo P
Actas Dermosifiliogr (Engl Ed); 2018 Mar; 109(2):177-178. PubMed ID: 28802491
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
